Old National Bancorp Biogen Inc. Transaction History

Old National Bancorp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	BUY	$252.44 - $306.72 $185,543 - $225,439	735 New	735 $203,000
Q4 2020 Jan 19, 2021	SELL	$236.26 - $355.63 $419,125 - $630,887	-1,774 Closed	0 $0
Q3 2020 Oct 29, 2020	SELL	$264.77 - $305.71 $103,525 - $119,532	-391 Reduced 18.06%	1,774 $503,000
Q2 2020 Jul 27, 2020	SELL	$258.66 - $342.55 $101,912 - $134,964	-394 Reduced 15.4%	2,165 $579,000
Q1 2020 Apr 24, 2020	SELL	$268.85 - $341.04 $554,368 - $703,224	-2,062 Reduced 44.62%	2,559 $810,000
Q4 2019 Jan 16, 2020	SELL	$220.06 - $304.07 $3.09 Million - $4.27 Million	-14,048 Reduced 75.25%	4,621 $1.37 Million
Q3 2019 Oct 22, 2019	SELL	$217.44 - $243.88 $1,087 - $1,219	-5 Reduced 0.03%	18,669 $4.35 Million
Q2 2019 Jul 15, 2019	BUY	$219.29 - $241.72 $357,004 - $393,520	1,628 Added 9.55%	18,674 $4.37 Million
Q1 2019 Apr 30, 2019	BUY	$216.71 - $338.96 $832,599 - $1.3 Million	3,842 Added 29.1%	17,046 $4.03 Million
Q4 2018 Jan 31, 2019	BUY	$278.5 - $352.75 $685,667 - $868,470	2,462 Added 22.92%	13,204 $3.97 Million
Q3 2018 Oct 26, 2018	BUY	$293.51 - $383.83 $2.59 Million - $3.39 Million	8,830 Added 461.82%	10,742 $3.8 Million
Q2 2018 Jul 26, 2018	BUY	$257.52 - $306.91 $492,378 - $586,811	1,912 New	1,912 $555,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Old National Bancorp , based on Form 13F filings with the SEC.

Stay updated on Old National Bancorp with notifications on news.